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INTRODUCTION
The two adult types of bone marrow (BM) can be distinguished: the red marrow consisting of
hematopoietic tissue, including Hematopoietic Stem Cells (HSCs) capable of producing around 500
billion blood cells per day; and the yellow marrow mainly made up of fat cells. BM contains two types of
stem cells: hemopoietic (which can produce blood cells) and stromal (which can produce fat, cartilage
and bone).
Mesenchymal Stem Cells (MSCs), first described in 1970 in BM,1 emerged as an extremely promising
therapeutic cell based agent for tissue regeneration and were broadly characterized in that sense.2,3
In vitro studies demonstrated that MSCs present attractive characteristics like immune-regulatory
effects; capacity to stimulate neovascularization, endogenous stem cell proliferation and
differentiation, capacity to modify the micro-environment, prevent scarification, fibrosis and aptitude to
differentiate into various mesoderm derived tissue. Notably, myocytes and cardiomyocyte
differentiation ability was shown in multiple studies.4–9 All together these properties drove enthusiasm
for MSCs and particularly BM derived MSCs (BM-MSCs) use in cardiac regeneration. MSCs represent
0.001 to 0.01% of BM nucleated cells and, it is now broadly accepted that MSCs cultures represent a
mix of various cells with various degrees of “stemness”.10,11
The unforeseen discovery that HSCs isolated from BM present the ability to repair infarcted
myocardium12 also prompted extensive research in this direction. Though, HSCs only represent
,0.01% of BM mononucleated cells, and there expansion in vitro remains elusive,13 therefore, clinical
trials to date relied on whole BM use, impairing the clear identification of which cellular actor drives the
observe effect.
Therefore, very short time after the publication of the first experimental study of the use of Bone
Marrow Cells (BMCs) for the treatment of post Myocardial Infarction (MI) heart failure (HF) in a small
animal model,14 clinical trials of this form of therapy started.15 This was followed by an extremely large
number of trials with mixed results,16–20 and even the alarming establishment of commercial clinics in
different countries.
All together, these findings lead in the last year to witness the publication of several trials in the field
using either whole BMCs or BM-MSCs. The results of the most recently publish results are reviewed
here with the hope of clarifying some of the major issues in the field. In addition, an article expressing
concerns regarding some of the early trials is described.
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TIME
The Timing in Myocardial Infarction Evaluation “TIME” trial is a multicenter 2 by 2 randomized, placebo
controlled trial performed as part of the Cardiovascular Cell Therapy Research Network (CCTRN)
sponsored by the National Heart Lung and Blood Institute (NHLBI). The objectives of the trial was to
determine the effect of timing of intracoronary injection of 1.5 £ 108 autologous BM derived cells on
recovery of Left Ventricle (LV) function after successful primary Percutaneous Coronary Intervention
(PCI) for anterior ST-Elevation Myocardial Infarction (STEMI).21 Overall, 120 patients were recruited.
The inclusion criteria included patients with an ejection fraction equal to or less than 0.45 after PCI.
Cells were injected 3 or 7 days after PCI. The primary end points were global and regional LV function
at 6 months after treatment.
This is a very well designed trial representing real life conditions encountered in many centers.
In spite of the relatively small number of patients dealt with in each center, the trial is likely to influence
practice by dampening some of the prevailing enthusiasm for infusing unmodified BM mononuclear
cells into the coronaries at 3 or 7 days after MI. Indeed, no significant influence in either treatment
group versus placebo on both end points was observed.
SWISS-AMI
The four-month results of this trial were published in Circulation earlier this year.22 Like TIME,
SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI) trial was
designed to examine the effect of timing of intracoronary injection of 10mL of mononuclear BM derived
cells at different interval, 3–4 days or 5–7 weeks after successful primary PCI.23 The authors
randomized 200 patients to controls, early and late cell infusion. The primary end point was left
ventricular function determined by cardiac MRI, at different time points. The current publication relates
to the 4month results. At this point, there was no difference in the primary end point between the three
groups. Although the period of follow up was very short, the findings confirm those of the TIME trial.
CELLWAVE
This trial was designed to test the possible beneficial effect of application of shock waves to the heart
24 h before intracoronary infusion of BM derived cells in patients with chronic post infarction HF.24
The authors randomized patients to placebo (n ¼ 20), high dose (n ¼ 40) and low doses (n ¼ 42)
shock waves. The primary endpoint was to assess a change in global left ventricular ejection fraction
(LVEF), measured at 4 months after treatment. They observed a modest improvement in LVEF from 1%
in the placebo group to 3.5% in the shockwave þ BM-MSCs group. Regional wall thickening also
improved modestly from 0.5% in the placebo group to 3.6% in the shockwaveþ BM-MSCs group. This
trial highlights the need for additional modalities to improve the results of these procedures.
POSEIDON
This early trial of PercutaneOus StEm cell Injection Delivery effects On Neomyogenesis (POSEIDON)
examines the use of autologous versus allogenic BM-MSCs injected into themyocardium through the trans
endocardial route in patients with post myocardial infarction HF.25 The authors randomized patients
(5 in each group) to autologous versus allogenic MSCs, in the absence of a control group.26 The endpoints
werea combinationof clinical andhemodynamicparameterswithemphasisonsafetyprofile at onemonth.
The results showed that both types of cells were safe and produced comparable improvements in
endpoints, with little evidence of an immune reaction to the allogenic cells. Another interesting finding in
this trial was the benefit of injectionof a smaller number of cells (20million)was superior to larger numbers
(100–200million). This proof of principle trial suggest that the use of “off the shelf” allogenic MSCsmight
be feasible in the future, and strengthens the need for processing BM derived cells before injection.
C-CURE
The Cardiopoietic stem Cell therapy in heart failURE (C-CURE), is a multi-center randomized placebo
controlled trial of feasibility, safety and efficacy of BM derived cardiopoietic mesenchymal stem cells
use in post myocardial infarction chronic HF. BM was harvested and isolated mesenchymal stem cells
were exposed to a cardiogenic “cocktail”. The cells were injected through the endocardium using a Nog
catheter (Medtronic). The end point was a composite score incorporating several hemodynamic and
clinical parameters.27
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Overall, 21 patients received the cell therapy and 15 acted as controls. Strict quality control and
testing for beginning myocardial differentiation was performed. The ejection fraction improved by
7% and the left ventricular end-systolic volume was reduced by 16mL in the treatment group as
compared to no change in the placebo. Similarly, there was improvement in the composite score in
the treatment group. This trial is a model of what can be done in this field. Longer term results of
this trial and similar trials are awaited with great interest.
DISCUSSION
Although the use of unprocessed BM derived cells for regenerative therapy is extremely attractive
because of availability and the short time required for its preparation, the collective evidence from the
MSCs
HSCs
Bone Marrow Cells
Culture of isolated MSCs
Unprocessed MSCs
Treatment of MSCs
TIME
SWISS-AMI
CELLWAVE
POSEIDON
C-CURE
Figure 1. Bone marrow cells used in the different trials. Flow chart of bone marrow cells used and treatments:
TIME, SWISS-AMI and CELLWAVE used unprocessed bone marrow cells including HSCs and MSCs. POSEIDON and
C-CURE used isolated and purified MSCs from bone marrow but while in POSEIDON the MSCs used were
unprocessed, in C-CURE the isolated MSCs were treated in culture with a “cardiogenic cocktail” prior injection.
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trials discussed above and previous clinical trials (elegantly reviewed in a meta-analysis of 33 trials)28
strongly suggests that we must move on.
We are awaiting with great interest the results of additional ongoing clinical trials such as: the
Transendocardial Autologous Cells (hMSC or hBMC) in ischemic Heart Failure Trial (TAC-HFT),29
PROspective randomized study of MEsenchymal stem cell THErapy in patients undergoing cardiac
Surgery (PROMETEUS), POSEIDON-DCM (studying MSCs therapy for the treatment of idiopathic dilated
cardiomyopathy) and the larger scaled phase II intracoronary reinfusion of Bone marrow-derived
mononuclear cells (BM-MNC) on all-cause mortality the in Acute Myocardial Infarction (BAMI) trial.
Though, the overall results of the large number of clinical trials already performed suggest that even
if proven safe, and when using allogenous MSCs, modest improvement of patient condition sustained
on long term is observed.Procedures designed to enhance the performance of these cells seems
therefore to be warranted. Four main areas of research could be actively pursued. As far as HSCs are
concerned, new solutions have been developed recently for HSCs in vitro amplifications and should be
further tested for heart failure treatment.30
As for MSCs, pre-treatment of the cells and there reprogramming towards cardiac fate prior to injection
seems be the direction of choice based on the better results observed with C-CURE. New modifications
via genetic alteration or Wnt and TGF-b pathway targeting could be further persued. BM-MSCs might also
not be the candidate of choice for heart therapy, and alternative source of MSCs could be tested.
IndeedMSCs can be isolated from a broad array of tissues (not exhaustively: adipose tissues, cord blood,
placenta etc.) that present acute in vitro and preclinical capacity of differentiation into
cardiomyocytes.31–34 Nevertheless, the same restricted improvementmight also be seenwith theseMSCs.
Evidence of pre-clinical and clinical data suggest that most of the beneficial effect of BM-MSCs treatment
rely on their paracrine effects more than direct cardiomyocyte differentiation. In that case, and considering
the safety of their injection and there immuno regulatory effect, MSCs use could be rethought as a
complement toother cell based therapies (like cardiac stemcells). Indeed, as stressed in theprevious issue
of the Journal,35 alternative methods using cardiac derived stem cells, exploiting the self-renewal capacity
of the differentiated myocardial cell, or cell reprogramming must be actively pursued.
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